Table 3.

Trends in Glioma Incidence-Based Mortality Rates ^a (1995-2018): the SEER-9 registry database.

Characteristic	Overall (1995-2018) b
	APC (95%CI)	P Value
Overall	-0.4 (-0.6 to -0.2)	<.001
Sex
Male	-0.3 (-0.6 to -0.1)	0.018
Female	-0.5 (-0.8 to -0.2)	0.001
Race
White	-0.2 (-0.4 to -0.1)	0.013
Black	0.0 (-0.6 to 0.7)	0.902
Other c	-0.1 (-0.8 to 0.6)	0.815
Age at Diagnosis/Death, y
<20	0.0 (-0.9 to 1.0)	0.932
20-39	-0.9 (-1.5 to -0.2)	0.014
40-59	-1.0 (-1.3 to -0.7)	<.001
60-79	-0.3 (-0.6 to -0.1)	0.010
≥80	1.0 (0.4 to 1.6)	0.001
Median Household Income
<75000	1.1 (0.6 to 1.6)	<.001
≥75000	-1.6 (-2.2 to -1.0)	<.001
Rural-Urban
Urban	0.2 (0.0 to 0.4)	0.059
Rural	-1.4 (-1.9 to -0.9)	<.001
Histologic Type
Glioblastoma	0.1 (-0.1 to 0.3)	0.188
Non-glioblastoma astrocytoma	-2.1 (-2.6 to -1.5)	<.001
Oligodendroglial tumors	-0.5 (-1.5 to 0.6)	0.391
Ependymoma	0.4 (-0.8 to 1.6)	0.527
Glioma, NOS	-1.0 (-1.8 to -0.2)	0.013
WHO Grade
I	NR d	NR d
II	-2.0 (-2.5 to -1.6)	<.001
III	-0.3 (-1.2 to 0.6)	0.512
IV	0.1 (-0.1 to 0.3)	0.188
Unknown	-0.9 (-1.7 to -0.1)	0.038
Glioblastoma
Tumor Extension e (1995-2015)
Localized	0.5 (0.2 to 0.7)	0.001
Regional	0.5 (-0.3 to 1.4)	0.191
Distant	NR d	NR d
Unknown	-4.6 (-6.2 to -2.9)	<.001
Tumor size f , cm
≤3.0	1.8 (1.2 to 2.4)	<.001
>3.0 to ≤5.0	1.7 (1.3 to 2.1)	<.001
>5.0	3.1 (2.4 to 3.8)	<.001
Unknown	-5.5 (-6.1 to -4.9)	<.001

^aRates were calculated as number of deaths per 100,000 person-years and age-adjusted to the 2000 US standard population.

^bBased on deaths during 1995-2018 and cases diagnosed during 1975-2018.

^cIncludes American Indian/Alaskan Native and Asian/Pacific Islander.

^dAPC could not be calculated because there were 0 death in one or more years.

^eTumor extension was based on cases diagnosed between 1983 and 2015.

^fTumor size was based on cases diagnosed between 1983 and 2018.

SEER, Surveillance, Epidemiology, and End Results; APC, annual percent change; NOS, Not otherwise specified; WHO, World Health Organization.